Anti-TNF

Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...

Trends in treatments for children with IBD can affect hospitalization and surgical needs. Noting rising use of biologics (infliximab) alongside fewer hospitalizations may be important for families and clinicians tracking...

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...

People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.

Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.

The findings show earlier and more frequent use of imaging, endoscopic assessment, anti-TNF therapy, and seton placement for active perianal fistulizing Crohn’s disease over recent years — practices that may affect...

The study suggests that anti‑TNF treatment in IBD is associated with weaker and less cross‑reactive antibody and memory B‑cell responses after COVID‑19 booster vaccination, which may reduce durability of protection and...

This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...

This study maps cell types in newly diagnosed pediatric Crohn's and links diagnostic cell patterns to disease severity and anti‑TNF treatment response. That could help predict which children are likely to benefit from...

Proactive monitoring of adalimumab levels could help keep drug concentrations therapeutic and reduce loss of response during maintenance therapy for ulcerative colitis.

Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...

This study maps cell-level signatures in newly diagnosed pediatric Crohn’s and links them to later severity and responses to anti-TNF treatment, which could help predict which children will respond to biologic therapy...

This study looks at how immunomodulators are actually used with biologic drugs in real-world practice when a national reimbursement policy forces biologic interruptions.

This review directly compares surgery-first versus biologic-first strategies for localized ileocaecal Crohn's disease and suggests early resection can lower later treatment needs and leave some patients off medication,...

This study reports a new engineered platform that can catalytically degrade TNF‑α, the same inflammatory cytokine targeted by several IBD therapies. If translated to humans, it could offer longer‑lasting mucosal...

This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...

The FDA label clarifies that ZYMFENTRA (a TNF blocker) is indicated for maintenance treatment of moderate–severe Crohn’s disease and ulcerative colitis after prior infliximab, and it carries strong safety warnings...

Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...

If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...

If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...

This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a...

This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...

CVID-related enteropathy can resemble celiac disease or IBD, carries high morbidity and mortality, and often does not respond to standard immunoglobulin therapy — patients and clinicians need awareness of its distinct...

Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...

This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...

People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.

People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...

If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...

Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...

Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology and...

Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...

Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.

Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...

Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.

The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point...

Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...

The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...

The study suggests anti-TNF failure in Crohn's may be driven by pre-existing cytokine interaction networks and loss of regulatory feedback, which could help explain why some patients don't respond to TNF-blocking...

This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...